PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 06 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1234% % -19%
Debt-to-equity 9% % -18%
Return On Equity -59% % -101%
Return On Assets -54% % -105%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53,329,392 shares 2.7%
Common Stock, Shares, Outstanding 53,331,766 shares 2.7%
Entity Public Float $53,435,814 USD -35%
Weighted Average Number of Shares Outstanding, Basic 52,541,613 shares 1.9%
Weighted Average Number of Shares Outstanding, Diluted 52,541,613 shares 1.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $69,877,000 USD 19%
General and Administrative Expense $16,329,000 USD -39%
Operating Income (Loss) $86,206,000 USD -0.89%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $79,914,000 USD -6.8%
Income Tax Expense (Benefit) $2,172,000 USD
Net Income (Loss) Attributable to Parent $77,742,000 USD -32%
Earnings Per Share, Basic -1.48 USD/shares -30%
Earnings Per Share, Diluted -1.48 USD/shares -30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $37,983,000 USD -7.1%
Marketable Securities, Current $74,960,000 USD -42%
Cash, Cash Equivalents, and Short-term Investments $112,943,000 USD -38%
Assets, Current $115,227,000 USD -34%
Property, Plant and Equipment, Net $237,000 USD -42%
Operating Lease, Right-of-Use Asset $801,000 USD -30%
Other Assets, Noncurrent $297,000 USD 26%
Assets $116,562,000 USD -39%
Accounts Payable, Current $3,155,000 USD -52%
Accrued Liabilities, Current $7,857,000 USD 5.6%
Liabilities, Current $11,415,000 USD -21%
Operating Lease, Liability, Noncurrent $435,000 USD -48%
Liabilities $11,850,000 USD -22%
Accumulated Other Comprehensive Income (Loss), Net of Tax $84,000 USD -40%
Retained Earnings (Accumulated Deficit) $446,454,000 USD -21%
Stockholders' Equity Attributable to Parent $104,712,000 USD -41%
Liabilities and Equity $116,562,000 USD -39%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $18,266,000 USD -13%
Net Cash Provided by (Used in) Financing Activities $10,000 USD
Net Cash Provided by (Used in) Investing Activities $28,714,000 USD 9.7%
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 53,331,766 shares 2.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $10,465,000 USD 5.2%
Deferred Tax Assets, Valuation Allowance $117,542,000 USD 22%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross $117,807,000 USD 21%
Operating Lease, Liability $838,000 USD -30%
Depreciation $133,000 USD -88%
Payments to Acquire Property, Plant, and Equipment $4,000 USD -99%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $77,797,000 USD -32%
Property, Plant and Equipment, Gross $1,564,000 USD -16%
Operating Lease, Liability, Current $403,000 USD 14%
Operating Lease, Weighted Average Discount Rate, Percent 0.137 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $157,000 USD -45%
Deferred Tax Assets, Operating Loss Carryforwards $68,592,000 USD 38%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $4,032,000 USD 24%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $265,000 USD -28%
Share-based Payment Arrangement, Expense $5,924,000 USD -33%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%